^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Clear Cell Renal Cell Carcinoma

    Related cancers:
    22h
    HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, National Heart, Lung, and Blood Institute (NHLBI) | Trial completion date: Mar 2026 --> Mar 2029
    Trial completion date
    |
    cyclophosphamide
    1d
    Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery (clinicaltrials.gov)
    P2, N=62, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: May 2027 --> Oct 2028 | Trial primary completion date: May 2027 --> Oct 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Keytruda (pembrolizumab) • Cdactin-O (CBM588)
    2d
    Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study (clinicaltrials.gov)
    P2, N=54, Recruiting, Vanderbilt-Ingram Cancer Center | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet)
    3d
    Multi-omics analysis reveals key genes associated with clear cell renal cell carcinoma. (PubMed, PeerJ)
    Moreover, the experiments demonstrate that the migration and proliferation abilities of ccRCC cells are enhanced after knocking down PRDX2. These results suggest that PRDX2 may play a role in the progression of ccRCC and could potentially serve as a prognostic factor and therapeutic target for ccRCC.
    Journal
    |
    PRDX2 (Peroxiredoxin 2)
    3d
    Phase II study of axitinib intensification plus standard of care (SOC) compared to SOC alone after induction with nivolumab plus ipilimumab in mRCC patients without previous complete response (AxIn study). (2024-511397-70-00)
    P1/2, N=178, Recruiting, Consorzio Oncotech | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • axitinib
    3d
    VHIO24002: Moonlanding: A phase 2 study of pembrolizumab plus belzutifan, with or without lenvatinib, given before the main treatment for localized kidney cancer (renal cell carcinoma) (2024-519673-18-00)
    P1/2, N=90, Not yet recruiting, Vall D Hebron Institute Of Oncology
    New P1/2 trial
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Welireg (belzutifan)
    5d
    DUAL-NK RCC: Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=36, Recruiting, Beijing Biotech
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1) • CA9 (Carbonic anhydrase 9)
    |
    fludarabine IV
    5d
    Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 (clinicaltrials.gov)
    P2, N=18, Active, not recruiting, National Cancer Institute (NCI) | N=60 --> 18 | Trial completion date: Mar 2026 --> Apr 2027
    Enrollment change • Trial completion date
    |
    SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase)
    |
    adavosertib (AZD1775)
    5d
    PRadR: Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer (clinicaltrials.gov)
    P1/2, N=6, Completed, Centre Leon Berard | Suspended --> Completed | N=48 --> 6 | Trial completion date: Apr 2026 --> Jul 2025 | Trial primary completion date: Apr 2026 --> Jul 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    6d
    SLC16A3-Induced Lactate Remodeling Drives Immune Evasion in Clear Cell Renal Cell Carcinoma via an Autocrine GPR81-ERK-c-MYC Feedback Loop. (PubMed, Balkan Med J)
    SLC16A3-induced lactate reprogramming drives immune resistance in ccRCC via two converging mechanisms: extracellular lactate-mediated immunosuppression through M2 macrophage polarization and an autocrine GPR81-ERK-c-MYC glycolytic feedback loop. These findings highlight MCT4 blockade combined with immune checkpoint inhibition as a rational strategy to overcome immunotherapy resistance.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • LDHA (Lactate dehydrogenase A) • CD8 (cluster of differentiation 8) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • SLC16A3 (Solute Carrier Family 16 Member 3) • SLC16A4 (Solute Carrier Family 16 Member 4)
    6d
    Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies. (PubMed, Cancer)
    Fianlimab plus cemiplimab demonstrated modest clinical efficacy with an acceptable safety profile in patients with advanced malignancies across several tumor types mostly in treatment-naive patients. Further investigation is warranted.
    Journal • First-in-human
    |
    LAG3 (Lymphocyte Activating 3)
    |
    Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    6d
    Performance of [89Zr]girentuximab PET/CT in Predicting the Presence of Any Renal Malignancy: A Reanalysis of the ZIRCON Trial. (PubMed, Eur Urol)
    Other forms of kidney cancer can express the marker that the imaging agent can identify. The additional analysis showed that when positive, 98% of cases were correctly identified as any form of cancer.
    Review • Journal
    |
    CA9 (Carbonic anhydrase 9)
    |
    Rencarex (girentuximab)